Aclaris Therapeutics ACRS Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $7.83M-58.2% | $18.72M-40.1% | $31.25M+5.0% | $29.75M+340% | ||
| $2.09M-25.1% | $2.79M-18.4% | $3.42M-14.9% | $4.02M-14.6% | ||
| $52.65M+56.7% | $33.59M-65.9% | $98.38M+26.4% | $77.81M+77.6% | ||
| $21.97M-1.0% | $22.2M-31.5% | $32.41M+29.0% | $25.13M+6.4% | ||
| $454K-43.7% | $807K-6.5% | $863K+8.3% | $797K-13.7% | ||
| $84.2M-47.6% | $160.65M+24.9% | $128.61M+7.5% | $119.61M+24.0% | ||
| -$76.38M+46.2% | -$141.93M-45.8% | -$97.36M-8.4% | -$89.85M-0.1% | ||
| -975.9%-218pp | -758.1%-447pp | -311.6%-9.5pp | -302%+1,025pp | ||
| $7.64M-4.0% | $7.95M— | —— | —— | ||
| $11.45M+16.1% | $9.87M+15.9% | $8.51M+189% | $2.95M+339% | ||
| -$64.92M+50.8% | -$132.07M-49.3% | -$88.48M-1.8% | -$86.91M+4.4% | ||
| -829.6%-124pp | -705.4%-422pp | -283.1%+9.0pp | -292.1%+1,052pp | ||
| -$0.53+69.0% | -$1.71-34.6% | -$1.27+4.5% | -$1.33+18.4% | ||
| -$0.53+69.0% | -$1.71-34.6% | -$1.27+4.5% | -$1.33+18.4% | ||
| 490.2M+68.4% | 291M+4.6% | 278.1M+7.3% | 259.3M+16.7% | ||
| 490.2M+68.4% | 291M+4.6% | 278.1M+7.3% | 259.3M+16.7% | ||
| $2.3M— | —— | -$26.9M-672% | $4.7M-80.7% | ||
| -$64.41M+51.2% | -$131.86M-50.4% | -$87.69M-0.1% | -$87.58M+3.8% | ||
| —— | $86.91M+1,211% | $6.63M— | —— | ||
| $5.19M-59.0% | $12.67M-13.6% | $14.66M— | —— | ||
| $513K— | —— | $791K— | —— | ||
| $513K— | —— | $791K— | —— | ||
| $7.83M-58.2% | $18.72M-40.1% | $31.25M+5.0% | $29.75M+340% | ||
| $3.82M— | —— | —— | —— | ||
| -$76.38M+46.2% | -$141.93M-45.8% | -$97.36M-8.4% | -$89.85M-0.1% | ||
| -$75.92M+46.2% | -$141.12M-46.3% | -$96.49M-8.4% | -$89.06M-0.3% | ||
| -$75.92M+46.2% | -$141.12M-46.3% | -$96.49M-8.4% | -$89.06M-0.3% | ||
| -970.1%-216pp | -753.8%-445pp | -308.8%-9.5pp | -299.3%+1,014pp | ||
| -$76.38M+46.2% | -$141.93M-45.8% | -$97.36M-8.4% | -$89.85M-0.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Aclaris Therapeutics's revenue?
- Aclaris Therapeutics (ACRS) generated $8.4M in revenue over the trailing twelve months, down 52.9% year over year.
- Is Aclaris Therapeutics profitable?
- Aclaris Therapeutics is not currently profitable: it reported a net loss of $69.7M over the trailing twelve months, a -832.6% net margin.
- What are Aclaris Therapeutics's profit margins?
- Gross margin is 76.3% and operating margin is -961.9%, with a -832.6% net margin.
- What is Aclaris Therapeutics's earnings per share?
- Aclaris Therapeutics's diluted EPS over the trailing twelve months is $-0.56.
- Where does Aclaris Therapeutics's income statement data come from?
- Every line is extracted from Aclaris Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
